Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular Dystrophy
Exegenesis Bio and Modalis Therapeutics Corporation have announced a research collaboration and license agreement to advance MDL-201, a potential...
Tevard’s tRNA Therapy Targets Nonsense Mutations to Restore Full-Length Dystrophin in DMD
Tevard’s suppressor tRNA therapy could offer a new way to address nonsense mutations in Duchenne muscular dystrophy (DMD), potentially...
Satellos’ Duchenne Drug SAT-3247 Receives Official WHO Name: Forazapadin
Satellos Bioscience has announced that its investigational Duchenne muscular dystrophy (DMD) treatment SAT-3247 has officially received the International Nonproprietary...